Time-differentiated target temperature management after out-of-hospital cardiac arrest: a multicentre, randomised, parallel-group, assessor-blinded clinical trial (the TTH48 trial): study protocol for a randomised controlled trial

Kirkegaard, Hans; Rasmussen, Bodil S; de Haas, Inge; Nielsen, Jørgen Feldbæk; Ilkjær, Susanne; Kaltoft, Anne; Jeppesen, Anni Nørregaard; Grejs, Anders; Duez, Christophe Henri Valdemar; Larsen, Alf Inge; Pettilä, Ville Yrjö Olavi; Toome, Valdo; Arus, Urmet; Taccone, Fabio Silvio; Storm, Christian; Skrifvars, Markus B; Søreide, Eldar (2016). Time-differentiated target temperature management after out-of-hospital cardiac arrest: a multicentre, randomised, parallel-group, assessor-blinded clinical trial (the TTH48 trial): study protocol for a randomised controlled trial. Trials, 17(1), p. 228. BioMed Central 10.1186/s13063-016-1338-9

Preview

Text 2016_Pettilä_PubMed 27142588_Time-differentiated target temperature management.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (759kB) | Preview

BACKGROUND

The application of therapeutic hypothermia (TH) for 12 to 24 hours following out-of-hospital cardiac arrest (OHCA) has been associated with decreased mortality and improved neurological function. However, the optimal duration of cooling is not known. We aimed to investigate whether targeted temperature management (TTM) at 33 ± 1 °C for 48 hours compared to 24 hours results in a better long-term neurological outcome.

METHODS

The TTH48 trial is an investigator-initiated pragmatic international trial in which patients resuscitated from OHCA are randomised to TTM at 33 ± 1 °C for either 24 or 48 hours. Inclusion criteria are: age older than 17 and below 80 years; presumed cardiac origin of arrest; and Glasgow Coma Score (GCS) <8, on admission. The primary outcome is neurological outcome at 6 months using the Cerebral Performance Category score (CPC) by an assessor blinded to treatment allocation and dichotomised to good (CPC 1-2) or poor (CPC 3-5) outcome. Secondary outcomes are: 6-month mortality, incidence of infection, bleeding and organ failure and CPC at hospital discharge, at day 28 and at day 90 following OHCA. Assuming that 50 % of the patients treated for 24 hours will have a poor outcome at 6 months, a study including 350 patients (175/arm) will have 80 % power (with a significance level of 5 %) to detect an absolute 15 % difference in primary outcome between treatment groups. A safety interim analysis was performed after the inclusion of 175 patients.

DISCUSSION

This is the first randomised trial to investigate the effect of the duration of TTM at 33 ± 1 °C in adult OHCA patients. We anticipate that the results of this trial will add significant knowledge regarding the management of cooling procedures in OHCA patients.

TRIAL REGISTRATION

NCT01689077.

Interest & Impact

Downloads

359 since deposited on 02 Aug 2016
22 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item